Advertisement
UK markets close in 3 hours 13 minutes

  • FTSE 100

    8,097.92
    +57.54 (+0.72%)
     

  • FTSE 250

    19,731.79
    +12.42 (+0.06%)
     

  • AIM

    755.45
    +0.76 (+0.10%)
     

  • GBP/EUR

    1.1670
    +0.0025 (+0.22%)
     

  • GBP/USD

    1.2508
    +0.0046 (+0.37%)
     

  • Bitcoin GBP

    51,186.21
    -2,032.29 (-3.82%)
     

  • CMC Crypto 200

    1,358.15
    -24.42 (-1.77%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.13
    +0.32 (+0.39%)
     

  • GOLD FUTURES

    2,341.70
    +3.30 (+0.14%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,990.94
    -97.76 (-0.54%)
     

  • CAC 40

    8,023.33
    -68.53 (-0.85%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?

Alex Carchidi, The Motley Fool
·4-min read
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?

With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (NASDAQ: ATAI) is having a rough go of things lately. When faced with such a discrepancy between recent performance and projected future returns, investors are right to hesitate to invest in this super-risky biotech stock. Let's take a peek at what's going wrong with Atai so that we can figure out if it's capable of surviving in the near term, and if it is, whether that makes it a buy.

Continue reading